INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate…
News + Press
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate…
PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific gene medicines, today announced that…
Download the poster here.
PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…
PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for…
Philadelphia, PA – April 27, 2023 – Interius BioTherapeutics, a preclinical stage gene therapy company…
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…